HUTCHMED (China) (HCM) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Liquidia (LQDA) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 11.0% versus a loss of 10.6%. Over five years, LQDA leads with a +733.8% price change compared with -55.8% for HCM. Liquidia is the larger company by market cap ($2.51 billion vs $2.38 billion), about 1.1 times the size.
On valuation, Liquidia trades at a lower forward P/E (11.7x vs 52.7x for HUTCHMED (China)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | LQDA |
|---|---|---|
| Share price | $13.67 | $28.02 |
| Market cap | $2.38B | $2.51B |
| 1-day change | -4.27% | +5.02% |
| YTD return | +7.13% | -22.64% |
| 1-year return | -10.64% | +11.03% |
| 5-year return | -55.79% | +733.75% |
| P/E ratio (TTM) | 136.70 | 20.16 |
| Forward P/E | 52.74 | 11.66 |
| EPS (TTM) | $0.10 | $1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | — |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $93.61 |
| 52-week low | $9.77 | $21.94 |
| Distance from 52-week high | -16.29% | -70.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +61.01% | +77.27% |
| Average volume | 67.70K | 2.40M |
| Shares outstanding | 173.81M | 89.51M |
| Employees | 1,790 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed HCM by 21.7 percentage points over the past year.
- HUTCHMED (China) trades at a higher earnings multiple (136.7x vs 20.2x trailing P/E).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
HCM vs LQDA FAQ
Which is bigger, HUTCHMED (China) or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $2.51B compared with $2.38B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or LQDA?
LQDA returned +11.03% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HCM or LQDA?
LQDA has the lower trailing P/E at 20.2, versus 136.7 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are HUTCHMED (China) and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.